Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITRONAL vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitronal (nitroglycerin) is a vasodilator that works by releasing nitric oxide, which activates guanylate cyclase and increases cyclic guanosine monophosphate (c GMP) in vascular smooth muscle, leading to relaxation and dilation of peripheral arteries and veins, predominantly venous dilation.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute angina pectoris,Prophylaxis of angina pectoris,Acute myocardial infarction (adjunctive therapy),Congestive heart failure (off-label),Hypertensive emergency (off-label)
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
Initial intravenous infusion of 5 mcg/min, titrated by 5 mcg/min every 3-5 minutes to clinical effect; typical maintenance 10-200 mcg/min.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Terminal elimination half-life is 1-4 minutes (due to rapid hepatic metabolism via glutathione S-transferase). Clinical context: necessitates continuous IV infusion for sustained effect.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Nitroglycerin is extensively metabolized in the liver by glutathione S-transferases and also in erythrocytes and vascular smooth muscle cells via denitration to dinitrates and mononitrates, which are further conjugated.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Renal: ~60% as inactive metabolites; fecal: ~35% via bile; unchanged drug: <1%.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
~60% bound to plasma proteins (albumin).
Isosorbide mononitrate is less than 5% bound to plasma proteins.
3.3 L/kg (large Vd due to high lipophilicity; indicates extensive tissue distribution).
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Sublingual: ~40-60% (first-pass hepatic metabolism); oral: <10% (extensive first-pass); topical: ~100% (minimal first-pass).
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No dose adjustment required for renal impairment.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Severe hepatic impairment (Child-Pugh class C): reduce dose by 50% and monitor closely.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Intravenous infusion: 0.25-0.5 mcg/kg/min, titrate as needed; maximum 5 mcg/kg/min.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Initiate at lower end of dosing range (5 mcg/min) due to increased sensitivity; titrate slowly.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
None explicitly required by FDA for nitroglycerin products; however, caution is advised due to risk of severe hypotension and syncope.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension,Tachycardia,Headache,Methemoglobinemia (rare with high doses),Tolerance development with prolonged use
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitrates,Severe hypotension (systolic BP <90 mm Hg),Cardiac tamponade,Constrictive pericarditis,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil)
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Avoid alcohol consumption as it may enhance hypotensive side effects. No specific food restrictions.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
FDA Category C. First trimester: Risk of teratogenicity cannot be ruled out; animal studies show fetal abnormalities at high doses. Second/third trimester: Risk of fetal nitrite toxicity (methemoglobinemia), fetal bradycardia, and reduced uteroplacental blood flow. Use only if maternal benefit outweighs fetal risk.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Excreted in breast milk in small amounts; M/P ratio unknown. Potential for infant methemoglobinemia and hypotension. Caution advised; consider alternative therapy or monitor infant for signs of cyanosis or hypotension.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
No specific dose adjustment established, but increased plasma volume may reduce drug levels; start at low end of dosing range and titrate to effect. Avoid bolus doses due to risk of severe hypotension and fetal bradycardia.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
Nitroglycerin is used for acute angina and perioperative hypertension. Administer sublingually for rapid onset; avoid in patients with hypertrophic obstructive cardiomyopathy, severe aortic stenosis, or concurrent phosphodiesterase-5 inhibitor use. Monitor for hypotension and reflex tachycardia. Tolerance develops with continuous exposure; use intermittent dosing schedules. Intravenous formulations require non-PVC tubing due to drug adsorption.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Place tablet under tongue or spray onto oral mucosa; do not swallow.,Sit or lie down when using to prevent fainting from low blood pressure.,If chest pain persists after 5 minutes, call emergency services immediately.,Store in original container, tightly closed, away from heat and moisture.,Do not use if taking erectile dysfunction medications like sildenafil within the past 24-48 hours.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITRONAL vs MONOKET, answered by our medical review team.
NITRONAL is a Nitrate Vasodilator that works by Nitronal (nitroglycerin) is a vasodilator that works by releasing nitric oxide, which activates guanylate cyclase and increases cyclic guanosine monophosphate (c GMP) in vascular smooth muscle, leading to relaxation and dilation of peripheral arteries and veins, predominantly venous dilation.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITRONAL and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITRONAL is: Initial intravenous infusion of 5 mcg/min, titrated by 5 mcg/min every 3-5 minutes to clinical effect; typical maintenance 10-200 mcg/min.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITRONAL and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITRONAL is classified as Category C. FDA Category C. First trimester: Risk of teratogenicity cannot be ruled out; animal studies show fetal abnormalities at high doses. Second/third trimester: Risk of fetal nitrite to. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.